Takeaway
Specific immune responses related to amyotrophic lateral sclerosis (ALS) genetic variants may contribute to differences in survival times.
Why this matters
Although previous studies have found elevated levels of inflammatory cytokines in people with ALS, the people examined were not genotyped for ALS-related mutations. The findings suggest that potential biomarkers associated with ALS prognosis may be useful as therapeutic targets.